HIGHLIGHTS
SUMMARY
Dabrafenib, a specific BRAF inhibitor, and trametinib, a MEK inhibitor, are two available molecules approved in Europe and the USA for the treatment of metastatic melanoma with BRAF-V600E or V600K mutations. Until now, only two desensitization protocols for dabrafenib have been reported, the first one for an immediate hypersensitivity reaction and the second for a delayed hypersensitivity reaction, toxic epidermal necrolysis. Despite the new regimen, 2 days later, the patient developed another episode of urticaria accompanied by malaise and nausea. The patient received gradually increasing doses ofdoses dabrafenib, as shown Table in 1 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.